Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Patients can now get the starting 2.5 mg dose for $299 per month
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Subscribe To Our Newsletter & Stay Updated
